Post-COVID pain syndrome: a review of international observations

The novel coronavirus infection is commonly referred to as COVID-19, sometimes by the name of the causative agent of a respiratory viral infection, as SARS-CoV-2. Frequently, the course of COVID-19 is divided into three main periods: acute COVID-19 (up to 4 weeks), post-acute COVID-19 (from 4 to 12 weeks), post-COVID (post-COVID; from 12 weeks to 6 months). If a more protracted course of COVID (over 6 months) is discussed, the term “long-COVID” is used. All observations demonstrated a high incidence of pain syndromes of various localization in the post-COVID period and long-COVID. According to survey data, 92.3% of patients with COVID-19 reported musculoskeletal problems at the time of admission. Pain syndrome is observed in 56.3% of cases 1 month after hospitalization. Three months after COVID-19, myalgia was observed in 40.55% of cases, joint pain in 39.18%, back pain in 31.62%, and lower back pain in 24.74%. After 6 months, joint pain continues to be observed in 18.59% of patients, myalgia – in 15.09%, back pain – in 14.39%, lower back pain – in 11.23%. In 50.8% of cases, patients reported new-onset pain, of which 38.5% had pain of moderate severity (≥3 points on the visual analog scale). Patients with new-onset pain during COVID had worse quality of life indicators and a negative correlation with the pain syndrome severity, which significantly hampered recovery. Data from a meta-analysis that included 47,910 patients with long-COVID and with a protracted course of COVID indicate that 19% of them had pain in the joints of various localization. The direct cytopathic effect of SARS-CoV-2 and the systemic immune inflammation that occurs in response to infection cause damage to the joint tissue. According to the Guidelines for the Treatment of Patients with the Consequences of COVID-19, it is recommended to use slow acting structure-modifying drugs – SYSADOA – in the pharmacological treatment regimen for patients with osteoarthritis, among which parenteral forms of pharmaceutically standardized drugs – chondroitin sulfate (CS) and glucosamine sulfate (GS) are preferred. GS and CS are inhibitors of the signaling cascade of the nuclear factor NF-κB, which is involved in the realization of biological effects of a pro-inflammatory cytokine (tumor necrosis factor α), the excessive activity of which is associated with the cytokine storm in COVID-19.

1. Ramakrishnan RK, Kashour T, Hamid Q, et al. Unraveling the mystery surrounding postacute sequelae of COVID-19. Front Immunol. 2021 Jun 30;12:686029. doi: 10.3389/fimmu.2021.686029. eCollection 2021.

2. National Institute for Health and Care Excellence. COVID-19 Rapid Guideline. In: Managing the Long-Term Effects of COVID-19. 2020. Available from: https://www.nice.org.uk/guidance/ng188

3. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-15. doi: 10.1038/s41591-021-01283-z

4. Centers for Disease Control and Prevention. Post-Covid Conditions. In: Information for Healthcare Providers. 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covidconditions.html

5. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-64. doi: 10.1038/s41586-021-03553-9

6. Rello J, James A, Reyes LF. Post-acute COVID-19 Syndrome (PACS): A public health emergency. Anaesth Crit Care Pain Med. 2021;40(3):100882. doi: 10.1016/j.accpm.2021.100882

7. Ahmad MS, Shaik RA, Ahmad RK. «LONG COVID»: an insight. Eur Rev Med Pharmacol Sci. 2021 Sep;25(17):5561-77. doi: 10.26355/eurrev_202109_26669

8. Jarrott B, Head R, Pringle KG, et al. «LONG COVID» – A hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol Res Perspect. 2022;10(1):e00911. doi: 10.1002/prp2.911

9. Sapkota HR, Nune A. Long COVID from rheumatology perspective – a narrative review. Clin Rheumatol. 2022;41(2):337-48. doi: 10.1007/s10067-021-06001-1

10. Summary of ICD coding for COVID-19. Available at: https://www.who.int/classifications/icd/COVID-19-coding-icd10.pdf

11. Bakilan F, Gökmeni G, Ortanca B. Musculoskeletal symptoms and related factors in postacute COVID-19 patients. Int J Clin Pract. 2021;75(11):e14734. doi: 10.1111/ijcp.14734

12. Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428-42. doi: 10.1177/01410768211032850

13. Ayres JS. A metabolic handbook for the COVID-19 pandemic. Nat Metab. 2020;2(7):572-85. doi: 10.1038/s42255-020-0237-2

14. Klok FA, Boon GJAM, Barco S, et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020 Jul 2;56(1):2001494. doi: 10.1183/13993003.01494-2020. Print 2020 Jul.

15. Vremennyye metodicheskiye rekomendatsii «Profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19)». Versiya 15 (22.02.2022). Minzdrav Rossii [Interim guidelines “Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)”. Version 15 (02/22/2022). Ministry of Health of Russia. 245 p. Available from: https://static0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf (accessed 02.03.2022).

16. Metodicheskiye rekomendatsii Rossiyskogo nauchnogo meditsinskogo obshchestva terapevtov (RNMOT) po lecheniyu bol'nykh s posledstviyami COVID-19 «Osobennosti techeniya Long-COVID infektsii. Terapevticheskiye i reabilitatsionnyye meropriyatiya» (utverzhdeny na XVI natsional'nom kongresse terapevtov 18.11.2021) [Guidelines of the Russian Scientific Medical Society of Therapists (RNMOT) for the treatment of patients with the consequences of COVID-19 “Peculiarities of the course of Long-COVID infection. Therapeutic and rehabilitation measures” (approved at the XVI National Congress of Therapists on November 18, 2021)]. Moscow; 2021. 217 p. Available from: https://www.rnmot.ru/public/uploads/2022/rnmot/METODICHESKIYe%20REKOMENDATSII.pdf (accessed 02.03.2022) (In Russ.).

17. Karateev AE, Amirdzhanova VN, Nasonov EL, et al. «Post-COVID syndrome»: The focus is on musculoskeletal pain. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2021;59(3):255-62. doi: 10.47360/1995-4484-2021-255-262 (In Russ.).

18. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020 Aug 11;324(6):603-5. doi: 10.1001/jama.2020.12603

19. Karaarslan F, Guneri FD, Kardes S. Postdischarge rheumatic and musculoskeletal symptoms following hospitalization for COVID-19: prospective follow-up by phone interviews. Rheumatol Int. 2021;41:1263-71. doi: 10.1007/s00296-021-04882-8

20. Karaarslan F, Guneri FD, Kardes S. Long COVID: rheumatologic/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months. Clin Rheumatol. 2022;41:289-96. doi: 10.1007/s10067-021-05942-x

21. Ojeda A, Calvo A, Cunat T, et al. Characteristics and influence on quality of life of new-onset pain in critical COVID-19 survivors. Eur J Pain. 2022;26(3):680-94. doi: 10.1002/ejp.1897

22. Hossain MA, Hossain KMA, Saunders K, et al. Prevalence of Long COVID symptoms in Bangladesh: a prospective Inception Cohort Study of COVID-19 survivors. BMJ Glob Health. 2021;6(12):e006838. doi: 10.1136/bmjgh-2021-006838

23. Gonzalez-Andrade F. Post-COVID-19 conditions in Ecuadorian patients: an observational study. Lancet Reg Health Am. 2022;5:100088. doi: 10.1016/j.lana.2021.100088

24. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv. 2021;2021.01.27.21250617. doi: 10.1101/2021.01.27.21250617

25. Malik P, Patel K, Pinto C, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL) – A systematic review and meta-analysis. J Med Virol. 2022 Jan;94(1):253-62. doi: 10.1002/jmv.27309. Epub 2021 Sep 7.

26. Amelot A, Jacquot A, Terrier L-M, et al. Chronic low back pain during COVID-19 lockdown: is there a paradox effect? Eur Spine J. 2022 Jan;31(1):167-75. doi: 10.1007/s00586-021-07049-y. Epub 2021 Nov 2.

27. Licciardone JC. Impact of COVID-19 on utilization of nonpharmacological and pharmacological treatments for chronic low back pain and clinical outcomes. J Osteopath Med. 2021 Mar 29;121(7):625-33. doi: 10.1515/jom2020-0334

28. Endstrasser F, Braito M, Linser M, et al. The negative impact of the COVID-19 lockdown on pain and physical function in patients with end-stage hip or knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2020 Aug;28(8):2435-43. doi: 10.1007/s00167-020-06104-3. Epub 2020 Jun 18.

29. Andrade BS, Siqueira S, de Assis Soares WR, et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021 Apr 18;13(4):700. doi: 10.3390/v13040700

30. Chen JS, Alfajaro MM, Chow RD, et al. Nonsteroidal anti-inflammatory drugs dampenthe cytokine and antibody response to SARSCoV-2 infection. J Virol. 2021;95:e00014-21. doi: 10.1128/JVI.00014-21

31. Wong AY, MacKenna B, Morton CE, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an Open SAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021 Jul;80(7):943-51. doi: 10.1136/annrheumdis-2020-219517. Epub 2021 Jan 21.

32. Jakiela JT, Waugh EJ, White DK. Walk at least 10 minutes a day for adults with knee osteoarthritis: recommendation for minimal activity during the COVID-19 pandemic. J Rheumatol. 2021 Feb;48(2):157-9. doi: 10.3899/jrheum.200914. Epub 2020 Aug 15.

33. Garcia LM, Birckhead BJ, Krishnamurthy P, et al. An 8-week self-administered at-home behavioral skills-based virtual reality program for chronic low back pain: double-blind, randomized, placebo-controlled trial conducted during COVID-19. J Med Internet Res. 2021 Feb 22;23(2):e26292. doi: 10.2196/26292

34. Gromova OA, Torshin IYu, Zaychik BTs, et al. Differences in the standardization of medicinal products based on extracts of chondroitin sulfate. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya = FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(1):50-62. doi: 10.17749/2070-4909/farmakoekonomika.2021.083 (In Russ.).

35. Gromova OA, Torshin IYu, Lila AM, et al. Molecular mechanisms of myoprotectiveaction of chondroitin sulfate and glucosamine sulfate in sarcopenia. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):117-24. doi: 10.14412/2074-2711-2019-1-117-124 (In Russ.).

36. Gromova OA, TorshinIYu, Lila AM, et al. Systematic study review on antitumor effects of glucosamine and chondroitin sulfate cartilage protectors. RMZh. Meditsinskoye obozreniye = RMJ. Medical Review. 2019;3(4-I):4-10. Available from: https://elibrary.ru/item.asp?id=38243356 (accessed 02.03.2022) (In Russ.).

37. Torshin IYu, Gromova OA, Lila AM, Limanova OA. Systematic analysis of the molecular pathophysiology of tenosynovitis: promise for using chondroitin sulfate and glucosamine sulfate. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(2):64-71. doi: 10.14412/2074-2711-2020-2-64-71 (In Russ.).

38. Mazzucchelli R, Rodriguez-Martin S, Garcia-Vadillo A, et al. Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study. PLoS ONE. 2021;16(7):e0253932. doi: 10.1371/journal.pone.0253932

39. Torshin IYu, Lila AM, Gromova OA. Hepatoprotective effects of chondroitin sulfate and glucosamine sulfate. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya = FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(4):537-47. doi: 10.17749/2070-4909/farmakoekonomika.2021.112 (In Russ.).

40. Zolotovskaya IA, Davydkin IL. Aantiresorptive-cytokine effects of chondroprotective therapy in patients with lower back pain. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(4):65-71. doi: 10.17116/jnevro202012004165 (In Russ.).

41. Torshin IYu, Lila AM, Naumov AV, et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya = FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):388-99. doi: 10.17749/2070-4909/farmakoekonomika.2020.066 (In Russ.).

42. Torshin IYu, Gromova ОА, Chuchalin АG, Zhuravlev YuI. Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drugbased COVID-19 therapy. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya = FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(2):191-211. doi: 10.17749/2070-4909/farmakoekonomika.2021.078 (In Russ.).